Research programme: protein kinase inhibitors - TargeGen

Drug Profile

Research programme: protein kinase inhibitors - TargeGen

Alternative Names: TG-100948; TG-101095; TG-101209

Latest Information Update: 30 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TargeGen
  • Class Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors; Platelet-derived growth factor inhibitors; Proto oncogene protein c ret inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema; Myeloproliferative disorders; Retinal vascular occlusion

Most Recent Events

  • 30 Aug 2011 No development reported - Preclinical for Age-related macular degeneration in USA (Topical)
  • 30 Aug 2011 No development reported - Preclinical for Choroidal neovascularisation in USA (Topical)
  • 30 Aug 2011 No development reported - Preclinical for Diabetic macular oedema in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top